Last reviewed · How we verify
NCT06149429
Virtual Reality at End-of-life
NA trial testing Personalized virtual reality experience in End of Life in 9 participants. Completed in 15 July 2024.
15 July 2024
Quick facts
| Lead sponsor | State University of New York at Buffalo |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 9 |
| Start date | 23 October 2023 |
| Primary completion | 15 July 2024 |
| Estimated completion | 15 July 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Personalized virtual reality experience
Conditions studied
- End of Life — all drugs for End of Life →
- Pain — all drugs for Pain →
- Nausea — all drugs for Nausea →
- Fatigue — all drugs for Fatigue →
Sponsor
State University of New York at Buffalo
Who can join
Eligibility, any sex, with End of Life or Pain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this research is to determine the effect that repeated, personalized virtual reality experiences have on symptom severity, comparing self-reported symptom severity both pre and post each session, and overtime across sessions. Researchers will also determine if this intervention results in a high rating of presence in VR, and if presence is related to the magnitude of the change in symptoms.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06149429
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for End of Life
Currently open trials in the same condition.
- NCT07147023 — Better Real-time Information on Documentation of Goals of Care for Engagement in Serious Illness Communication · NA · active not recruiting
- NCT06722352 — Palliative Care Education in Assisted Living for Dementia Care Providers (PCEAL-DCP) · NA · recruiting
- NCT07191184 — Identification of Obstacles and Levers to the Outpatient Care of Patients in Terminal Palliative Situations · recruiting
- NCT06071078 — Impact of a Protocol for Announcing Decision of Withholding and Withdrawing Life-sustaining Treatments on the Stress of · NA · recruiting
- NCT05861323 — Feasibility of the Comfort Measures Only Time Out (CMOT) · NA · active not recruiting
Other State University of New York at Buffalo trials
Trials by the same sponsor.
- NCT07072767 — Hybrid Dissemination Study of A Digital-Analog Intervention to Increase Live Donor Kidney Transplantation · NA · not yet recruiting
- NCT07140848 — CGM-Enhanced DPP to Prevent Type 2 Diabetes in Adults With Prediabetes · NA · not yet recruiting
- NCT07433959 — Neuromodulation to Improve Grasping Function After SCI · NA · not yet recruiting
- NCT07403539 — Speech Learning and Speech Production in Parkinson's Disease · NA · recruiting
- NCT05367362 — Minocycline Efficacy in Improving Neurological Outcome of Patients Who Undergo Endovascular Revascularization for Acute · Phase 2 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06149429 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by State University of New York at Buffalo
- Last refreshed: 19 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06149429.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing